Maternal T Cell Engraftment in SCID
Also known as: STR-SCID
Use
The Maternal T Cell Engraftment in SCID test is used to monitor the presence and proportion of maternal T cells in patients with severe combined immunodeficiency (SCID) prior to allogenic stem cell transplantation. SCID patients lack T cells, which can lead to complications such as graft-versus-host disease and difficulties in determining host T cell numbers necessary for diagnosis and treatment. This test helps in understanding the engraftment dynamics of maternal T cells, which can proliferate in the absence of host T cells.
Special Instructions
Samples for the Maternal T Cell Engraftment in SCID test should be collected to perform three tests: a buccal swab or brush from the patient, a peripheral blood sample from the biological mother, and a peripheral blood sample from the patient. If T-cell sorting is not completed before submission, additional charges for BMT Cell Isolation will apply.
Limitations
Diagnostic errors may occur due to rare sequence variations. The limit of detection for this test is 2 percent of the minor cell population present in the specimen. The test has not been cleared or approved by the U.S. Food and Drug Administration but is performed in a CLIA-certified laboratory and intended for clinical use.
Methodology
PCR-based (Fragment Analysis)
Biomarkers
Result Turnaround Time
5-9 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
2 mL
Container
Lavender (EDTA), pink (K2EDTA), or yellow (ACD solution A)
Storage Instructions
Ambient. Also acceptable: refrigerated. Ship overnight.
Causes for Rejection
Clotted or hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 72 hours |
| Frozen | Unacceptable |
Other tests from different labs that may be relevant